Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bubblegum-flavored kids’ Zyrtec

This article was originally published in The Tan Sheet

Executive Summary

FDA approves McNeil's proposed label changes and a bubblegum flavor for both Children's Zyrtec formulations, Allergy and Hives Relief (cetirizine 5 mg/5 mL), according to Aug. 14 letters. In addition to the new bubblegum-flavored, sugar-free formulation, the agency approves several manufacturing changes for Children's Zyrtec including the addition of a new manufacturing site for the products, a change in the order of ingredients, adjustment of process temperature and the introduction of a new 2-ounce. bottle size for Children's Zyrtec Allergy syrup. The agency approved Zyrtec for OTC use in November 2007 (1"The Tan Sheet" Nov. 19, 2007, In Brief)

You may also be interested in...



FDA approves Zyrtec OTC

The agency approves Zyrtec (cetirizine HCl) for nonprescription use, one week after it granted McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, approval to switch the allergy treatment's decongestant combination product, Zyrtec-D (1"The Tan Sheet" Nov. 12, 2007, p. 9). The prescription-strength product will be available OTC in stores starting in late January 2008, J&J says in a Nov. 16 release. The firm received approval for Zyrtec in 5 mg and 10 mg tablets, 5 mg and 10 mg chewable tablets and 1 mg/mL syrup. The once-daily drug is indicated for relieving indoor and outdoor allergy symptoms of sneezing, runny nose and watery eyes for up to 24 hours in adults and children; the drug also relieves itching due to hives, J&J says...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS102018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel